 HOUSTON, March 9, 2021 PRNewswire -- Marker Therapeutics, Inc. Nasdaq:MRKR, a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the fiscal year ended December 31, 2020. We are proud of our Companys continued progress, which has positioned us for a busy and productive year ahead, said Peter L. 